PUBLISHER: Visiongain | PRODUCT CODE: 1413736
PUBLISHER: Visiongain | PRODUCT CODE: 1413736
The global Precision Cancer Diagnostic Test Market is projected to grow at a CAGR of 16.1% by 2034.
“The Precision Cancer Diagnostic Test Market Report 2024-2034”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The increasing adoption of liquid biopsies in cancer diagnosis has significantly intensified market competitiveness, with companies actively entering this domain viewed as key drivers of clinical advancements. LabCorp's introduction of a novel blood test in June 2023 for detecting cancer-related biomarkers exemplifies this trend, potentially expediting effective treatments. Liquid biopsy, particularly valuable for those unable to undergo tissue biopsies, is gaining traction, notably in diagnosing advanced and metastatic cancer cases. Breakthroughs, such as the detection of cancer in diverse bodily fluids through liquid biopsy in March 2022, highlight the technology's expanding applications. The ongoing development of non-invasive liquid biopsies focusing on circulating tumor DNA and other markers holds promise for transforming cancer diagnostics by enabling real-time monitoring and early detection. Industry efforts to integrate liquid biopsy with advanced AI technologies, as seen in collaborations like GC Genome Corporation with KAIST, underscore the commitment to enhancing DNA mutation analysis. Noteworthy company initiatives, including Qiagen's acquisition of Verogen and BillionToOne's precise liquid biopsy device launch, highlights the industry's focus on growth, technological advancements, and product innovation, driving market expansion.
Precision cancer diagnostic tests utilize advanced technologies, such as next-generation sequencing (NGS) or mass spectrometry, which can be associated with high costs, posing challenges for accessibility, especially in resource-constrained regions. The elevated expenses linked to precision cancer diagnostics may act as a hindrance to market growth, restricting patient access to these advanced diagnostic tools. Despite the significant advantages offered by precision cancer diagnostics, including more accurate diagnoses and personalized treatment plans, the financial implications associated with these tests presents a formidable challenge for both healthcare systems and patients. For example, the FoundationOne CDx, priced at approximately US$5,800.0 per biopsy, delivers valuable information for treatment decisions but can impose a substantial financial burden on patients and healthcare systems. Guardant360, a liquid biopsy test by Guardant Health analyzing circulating tumor DNA, comes with a cost ranging from US$5,000 to US$6,500 per biopsy. While liquid biopsies are less invasive than tissue biopsies, their pricing remains a concern, potentially limiting access for certain patients, particularly those lacking comprehensive insurance coverage, and leading to potential delays in diagnosis and treatment decisions.
You need to discover how this will impact the precision cancer diagnostic test market today, and over the next 10 years:
This report tells you TODAY how the precision cancer diagnostic test market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:
The report also includes profiles and for some of the leading companies in the Precision Cancer Diagnostic Test Market, 2024 to 2034, with a focus on this segment of these companies' operations.
|
|
Overall world revenue for Precision Cancer Diagnostic Test Market, 2024 to 2034 in terms of value the market will surpass US$12,097.8 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
In summary, our 370-page report provides you with the following knowledge:
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Precision Cancer Diagnostic Test Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
3.2.2.2High Cost of Precision Cancer Diagnostic Tests
3.4.1Bargaining Power of Suppliers
12.10Japan Precision Cancer Diagnostic Test Market Analysis
12.11China Precision Cancer Diagnostic Test Market Analysis
12.12India Precision Cancer Diagnostic Test Market Analysis
12.13Australia Precision Cancer Diagnostic Test Market Analysis
12.14South Korea Precision Cancer Diagnostic Test Market Analysis
12.15Rest of Asia Precision Cancer Diagnostic Test Market Analysis
13.10Brazil Precision Cancer Diagnostic Test Market Analysis
13.11Mexico Precision Cancer Diagnostic Test Market Analysis
13.12Argentina Precision Cancer Diagnostic Test Market Analysis
13.13Rest of Latin America Precision Cancer Diagnostic Test Market Analysis